Yichang Renfu Pharmaceutical's Flurbiprofen Axetil Injection Receives Marketing Approval
Time：
2025-09-17
Recently, Yichang Humanwell Pharmaceutical Co., Ltd. received the Drug Registration Certificate for Flurbiprofen Axetil Injection, approved and issued by the National Medical Products Administration. This product was granted market approval as a Category 3 chemical drug, available in a specification of 5 ml: 50 mg, and is considered to have passed the consistency evaluation. It is indicated for postoperative and cancer-related pain management.
Flurbiprofen Ester Injection As a novel non-steroidal anti-inflammatory drug (NSAID), it is known for its Lipid microspheres Unlike traditional non-steroidal anti-inflammatory analgesics, this technology exhibits a degree of targeted action: once inside the body, the drug preferentially distributes to sites of injury and tumors. Flurbiprofen axetil is released from lipid microspheres and, under the action of carboxylesterase enzymes, rapidly hydrolyzes to form flurbiprofen. This flurbiprofen then inhibits prostaglandin synthesis, thereby exerting its analgesic effect.
The launch of Yichang Renfu's Flurbiprofen Ester Injection further enriches the company's product pipeline, and we will actively push forward the commercialization efforts for this product in the future.
Tags:
Related News
ABOUT US
CONTACT
Add：66 Tianjiahe Avenue, Baiyang Town, Baiyang,Industrial Park, High-tech Zone,Yichang City, Hubei Province, China.
Tel：+86-717-4065884 +86-717-4065888
E-mail：yctr@renfu.com.cn
Copyright © 2024 YICHANG TIANRUI BIOPHARM CO., LTD All Rights Reserved.